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Abstract 
                                                                                                                                                                                             
The synthetic retinoid 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene Carboxylic Acid 
(CD437/AHPN) has been shown to have an antiproliferative effect, as well as being a potent 
inducer of apoptosis, in many cancer cell lines. The mechanisms behind CD437s activities have 
been reported as cell-line dependent. In this master thesis, the anti-tumor effect of CD437 was 
elucidated in the two human malignant melanoma cell lines, FEMX1 and WM239.  
- CD437 was shown to have an antiproliferative effect in both cell lines. A reduction in 
cells relative to the control was first visually observed, and later confirmed by a cell 
count. As revealed by MTS, the reduction of viable cells was duration- and dosage 
dependent. 
- Treatment with CD437 caused a cell-line dependent cycle arrest, yielding an S phase- and 
a G1 phase arrest in FEMX1 and WM239 respectively, as demonstrated by flow 
cytometry. Western blot analysis revealed that the arrests were accompanied by up-
regulations of p53, p21 and E2F-1 protein levels. A down-regulation of cyclin D1 was 
found in FEMX1 cells. 
- Apoptosis was observed in both cell lines following treatment with CD437; 
Morphological features associated with apoptosis were seen in both cell lines. A cell 
count using trypan blue revealed an increase of dead cells after exposure to CD437. A 
TUNEL analysis demonstrated DNA fragmentation in WM239, but not in FEMX1. In 
both cell lines, cleavage of the initiator caspases 8 and -9 were observed, in addition to 
PARP cleavage. Cleavage of caspase 3 was found in FEMX1 cells.  
- An increase of the orphan nuclear receptor Nur77 was found using the western blot 
analysis, in treated the cells. In addition, activation of c-jun was observed in both cell 
lines following exposure to CD437. 
- Treatment with CD437 resulted in an activation of the p38/MAPK signaling pathway in 
both cell lines, as assessed by western blotting. Additionally, in the exposed FEMX1 cells 
the PI3K signaling pathway was activated.  
- Preliminary results suggest that an up-regulation of p53 caused by CD437 may be 
regulated by Nur77. The increase of p21 did not appear to be controlled by Nur77, which 
may suggest a p53-independent expression of p21.   
Malignant melanomas are notoriously resistant to chemotherapy, making the prognosis for 
patients with metastasis very poor. CD437 represent a potential new treatment option, however 
many more studies are needed to evaluate its effect both in vitro and in vivo. 
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Sammendrag 
 
Det har tidligere vært vist at den syntetiske retinoiden ”6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-
naphthalene Carboxylic Acid” (CD437/AHPN) har en antiprolifererende og apotose induserende 
effekt i mange kreft cellelinjer. De intracellulære mekanismene som forklarer effekten av CD437 
har imidlertid vist seg å variere mellom ulike cellenlinjer. Hensikten med denne masteroppgaven 
er å vurdere CD437s anti-tumor effekt i to humane maligne melanomcellelinjer; FEMX1 og 
WM239. 
- Det ble funnet at CD437 har en antiprolifererende virkning i begge cellelinjene. 
Virkningen viste seg som en reduksjon i antall celler i forhold til kontrollen. Dette ble 
først observert visuelt, og siden bekreftet ved celletelling. Ved bruk av en MTS analyse 
ble det funnet at nedgangen i levedyktige celler både var avhengig av konsentrasjon og 
varighet av behandling. 
- Flowcytometriske analyser viste at CD437 forårsaket ulik cellesyklus arrest; en S- og G1 
fase arrest ble observert i henholdsvis FEMX1 og WM239. Det ble videre påvist at 
cellesyklusarresten var assosiert med  oppregulering av  p53, p21 og E2F-1, som vist med 
western blotting. En nedgang i cyclin D1 ble funnet etter behandling i FEMX1 cellene. 
-  Apoptose ble observert i begge cellelinjene etter behandling med CD437. En celletelling 
med trypanblått påviste økt dødelighet etter behandilng i forhold til kontrollcellene. 
TUNEL analyse viste videre at CD437 forårsaket DNA fragmentering i WM239, men 
ikke i FEMX1 cellene. Kløyving av initiator caspase 8 og -9, samt PARP, ble funnet ved 
western blotting, i begge cellelinjene. Det ble i tillegg observert en kløyving av effektor 
caspase 3 i FEMX1 cellene. 
- Western blot analyser tyder på en oppgang i protein nivåene til  kjernereseptor Nur77 og 
aktivering av transkripsjonsfaktor p-c-jun, etter behandling med CD437.  
- CD437 behanling førte i begge cellelinjene til aktivering av p38/MAPK signalveien, 
mens PI3K veien kun ble aktivert i FEMX1 cellene.  
- Preliminære forsøk viste videre at oppregulering av p53, som følge av CD437 
behandling, er regulert av Nur77. Det økte p21 protein nivået synes imidlertid ikke å 
være styrt av Nur77, noe som videre tyder på at p21 ekspresjonen er uavhengig av p53. 
Malignt melanom har vist seg å være særs motstandsdyktig til kjemoterapi, og prognosen for 
pasienter med spredning er derfor svært dårlig. I lys av både våre - og tidligere funn, 
representerer CD437 et potensielt nytt behandlingstilbud. Det er dog nødvendig med flere 
undersøkelser for å evaluere dets effekt både in vitro og in vivo.  
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Abbreviations 
 
AIF   Apoptosis Inducing Factor 
AJCC   American Joint Committee on Cancer 
APAF-1  Apoptotic Protease-activating Factor-1 
APL Acute promyelocytic leukaemia 
ATP   Adenosine Triphosphate 
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Bid   BH3 interacting domain death agonist 
Bim   Bcl-2 like 11 
B-RAF  V-raf murine sarcoma viral oncogene homolog B1 
BSA   Bovine Serum Albumin 
BTB   β-mercapto bromophenol blue 
Caspase  Cysteine-dependent Aspartate-directed Proteases 
CD437 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene Carboxylic 
Acid  
CDC25  Cell division cycle 25  
CDK   Cyclin Dependent Kinase 
CHOP/GADD153 C/EBP homologous protein 
CICD   Caspase Independent Cell Death 
DISC   Death inducing Signaling complex 
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IAP   Inhibitor of apoptosis 
INK4   Inhibitor of cyclin dependent kinase 4 
LDH   Lactic Dehydrogenase 
MAPK   Mitogen-Activated Protein Kinase    
Mcl-1   Myeloid cell leukemia-1 
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MOMP  Mitochondrial Outer Membrane Permeabilization 
MTS 3-(4.5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) 
NFκB   Nuclear Factor kappa-light-chain-enhancer of activated B cells 
NR4A1  Nuclear receptor subfamily 4, group A, member 1 
N-RAS  Neuroblastoma RAS viral (v-ras) oncogene homolog 
Nur77/TR3/NGFB-1 Nuclear ophan receptor protein 
p14 INK4d  Inhibitor of cyclin-dependent kinase 4d 
p15 INK4b  Inhibitor of cyclin-dependent kinase 4b 
p16INK4a  Inhibitor of cyclin-dependent kinase 4a 
p18INK4c  Inhibitor of cyclin-dependent kinase 4c 
p21Cip1/WAF1 Cyclin-dependent kinase inhibitor 1a/ Wild-type Activating 
Fragment 
p27Kip1   Cyclin-dependent kinase inhibitor 1b 
p57Kip2   Cyclin-dependent kinase inhibitor 2 
PARP   Poly(ADP-ribose) polymers 
PBS   Phosphate buffered saline 
pRB   Retinoblastoma protein 
PS   Phosphatidyl Serine  
PVDF membrane Polyvinylidene Fluoride membrane 
RA Retinoic acid 
RAR Retinoic acid receptor 
RARE Retinoic acid receptor element 
RISC   RNA-induced signaling complex 
RNA   Ribonucleic acid 
RNAi RNA interference 
RXR Retinoic X receptor 
RXRE Retinoic X receptor 
SAPK/JNK  Stress-Activated Protein Kinase 
SDS-PAGE  Sodium Dodecyl Sulphate - polyacrylamide gel 
SiRNA Small/short interfering RNA  
SMAC/DIABLO Second mitochondria-derived activator of caspases/direct IAP-
binding protein 
TBS-T   Tris-Buffered Saline and Tween 20 
Tdt Terminal deoxynucleotidyl transferase 
TE-buffer  Trypsin/EDTA- buffer  
TNF-α   Tumor Necrosis Factor-α 
TNM   Tumor-Node-Metastasis 
TRADD Tumor necrosis factor receptor type 1-associated death domain 
protein 
TRAIL  TNF-related apoptosis-inducing ligand 
TRAIL  TNF-related apoptosis-inducing ligand 
TUNEL  Terminal Transferase dUTP Nick End Labeling 
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1.Introduction 
 
1.1 Aim of the study 
 
Much effort has been put into finding efficient treatments for human malignant 
melanoma, yet this form of cancer seems to be notoriously resistant to chemotherapy both 
in vivo and in vitro (1). There are per today, few good options for treatment of malignant 
melanoma that has reached an advanced stage, hence the prognosis is poor; only 14 
percent of patients diagnosed with metastatic melanoma survive for five years (2). It is 
therefore a precarious need to gain more knowledge about the disease in order to find 
more suitable treatments. 
Retinoids, small natural and synthetic molecules derived from vitamin A, have in the 
recent years evoked interest in the fields of cancer research due to their efficiency in 
treating certain types of cancer, both in vitro and in clinical trials (3;4). Due to the 
toxicity associated with the natural retinoids, focus has been cast on developing synthetic 
analogues, such as 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene Carboxylic 
Acid (CD437). This synthetic retinoid has so far shown promising results by selectively 
inducing apoptosis and cell cycle arrest in several cell-lines, including melanomas (1;5-
8). The mechanisms behind the anti-tumor effects of CD437 remain largely unknown, its 
ability to induce apoptosis and cell cycle arrests can, unlike the natural retinoids, be 
mediated independent of the retinoid receptors in the cell (8-10). 
The goal of this master study was to evaluate the effects of CD437 on two metastatic 
malignant melanoma cell lines (FEMX1 and WM239) grown in vitro, with respect to cell 
death, proliferation and cell cycle arrest, and to investigate possible mechanisms involved 
in these processes. 
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1.2 Background 
 
1.2.1 Cancer 
 
Most people living in the developed world have some sort of relation to the word 
‘cancer’. Being the third most common death-causing disease worldwide, cancer kills 
nearly 6 million people every year (11). 
 
 
Figure 1. Distribution of deaths caused by disease, 2004 (11). 
 
 
Cancer can affect living cells in every part of the human body, making it a variable and 
complex disease. Some traits, however, are thought to be shared by most human tumors. 
These hallmarks include; resistance to apoptosis, self-sufficiency in growth signals, 
insensitivity to anti-growth signals, limitless replicative potential, sustained angiogenesis, 
and tissue invasion (metastasis) and growth (12). 
 
The current understanding of cancer is as a multi-step process, where a mutation in the 
cell can give it certain advantages to survive and accumulate further mutations. The 
genetic alterations will stepwise transform the cell from normal to cancerous, comparable 
to the Darwinian evolution, though on a much smaller scale (12). 
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In the human cell, a series of intracellular systems co-operate to ensure that the DNA 
sequence information remains unaltered (13). Despite these careful monitoring systems, 
mutations in certain genes can potentially lead to cancer.  
 
Mutations occurring in both alleles of a tumor suppressor gene, lead to its loss of 
function, rendering the cell less capable of detecting and repairing other mutations. 
Mutation happening in a proto-oncogene, encoding proteins involved in regulation of cell 
growth and differentiation, can on the other hand augment its activity, making the cell 
more susceptible to uncontrolled cell division. MicroRNA genes encode short single-
strand RNA sequences that regulate the expression of other genes, either by causing their 
mRNA to be degraded, or by blocking the protein translation. Mutations in microRNA 
genes can hence affect the expression of both tumor suppressor genes and oncogenes 
(14). 
 
1.2.2 Malignant melanomas  
 
Malignant melanoma is the most aggressive form of skin cancer, arising in melanocytes, 
the pigment-forming cells of the skin. The disease is relatively rare, and accounts for only 
four percent of all dermatological cancers (2). There is, however, an increase of new 
cases, especially in Norway and Sweden (15). 
 
 
Figure 2. Malignant melanoma 
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Several factors are thought to increase the risk of developing melanomas, such as; over-
exposure to the sun, fair skin, presence of multiple birthmarks or freckles and a family 
history of melanoma (15). 
 
The American Joint Committee on Cancer (AJCC) recommends using a grading system 
to set an appropriate prognosis when dealing with melanomas, currently used is the 
Tumor-Node-Metastasis (TNM) criteria. In the TNM staging system, T represents tumor 
thickness and ulceration, N considers the amount of metastatic lymph nodes, and the M 
evaluates the sites of distant metastasis as well as the level of serum Lactic 
Dehydrogenase (LDH) (16). 
 
Both the Clark model and Breslow’s depth are used in order to grade a melanoma 
according to the TNM criteria. The Clark model is a model showing the stepwise 
transformation of a melanocyte into a melanoma (17), and Breslow’s depth is used to 
describe how deeply tumor cells have invaded the skin (18). 
 
 
Figure 3. The Clark model; grading the invasion of the melanoma in the skin (17). 
 
The transformation of a melanocyte into a malignant metastatic melanoma is thought to 
involve a sequential accumulation of mutations. Although much remains unknown, some 
main molecular changes leading to aggressive types of melanoma have been found (19).  
- Hyperactivation of the MAPK/ERK1/2 signaling pathway is common in 
melanomas, and is often due to mutations in genes coding for proteins such as 
NRAS or B-raf , thus leading to increased proliferation in these cells(20).  
- The PI3K/Akt signaling pathway is also frequently altered in melanomas, causing 
an increased survival.  Common mutation associated with this pathway are found 
in genes coding for Akt and PTEN (21).  
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- Mutations causing the transcription factor MITF to be up-regulated is commonly 
found in melanomas, leading to increased proliferation and survival (22). 
- In many aggressive melanomas, mutations in genes coding for inhibitors of the 
cell cycle, such as p14INK4d and p16INK4a, have been found, causing the cell to 
avoid apoptosis and senescence (23).  
1.2.3 Signaling  
 
In a well functioning organism, each cell must adapt to its environment. In order to do so, 
the cell has to monitor its surrounding environment, as well as communicate with other 
cells. Communication between cells involves receiving and transmitting signals, which 
can trigger specific short- or long term changes in the receiving cell. On a short term 
basis, cellular changes may include alterations in cellular metabolism, function or 
movement, whereas the long term changes usually involves modifications in gene 
expression and development (24). 
Binding of the ligand will either occur to certain receptors located on the cell surface, or 
the ligand may penetrate the cell membrane and bind to an intracellular receptor. Ligands 
that bind to cell surface receptors may cause a conformational change in the receptor, 
which can lead to an activation of a signal transduction pathway. In eukaryotic cells, the 
intracellular signal transduction pathways are highly conserved, and function in 
essentially the same way in cells from different species (24). 
 
The mitogen-activated protein kinase (MAPK) is a family of serine-threonine kinases, 
important in conveying extracellular signals to the nucleus, where they can alter the cells 
gen expression. The family consists of several members, where the best understood 
classes of MAPKs are;  Extracellular signal.regulated kinases 1 and 2 (ERK1/2) -, the 
stress-activated protein kinases (SAPK/JNK) - and the p38/MAPK pathways (25). 
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Figure 4. Major MAPK signaling cascades in mammalian cells (26) 
 
 
The ERK1/2/MAPK signal transduction pathway is central in several processes such as 
proliferation, growth arrest, cell survival, apoptosis, oncogenesis and differentiation, and 
can be triggered by a variety of signals such as hormones and growth factors (27). The 
effects of the ERK1/2 kinases, have in some studies been described as variable and 
sometimes opposing, depending on the strength and duration of the ERK1/2 activation 
(28). As previously described, proteins involved in this signaling pathway are often 
mutated in melanomas, leading to its hyperactivation. 
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The JNK - and p38/MAPK pathways can be triggered by a variety of environmental and 
genotoxic stress factors, and may cause an alteration in the expression of transcription 
factors, cytokines and cell cycle regulators, amongst others the Activator protein-1 (AP-
1), leading to a variety of cellular responses dependent on the cell type, duaration and 
strength of the signal (29;30). Both the JNK- and p38/MAPK pathways have been 
suggested to play a role in apoptosis (31). In addition, activated p38/MAPK has been 
shown to influence the expression of p53, an important regulator of both the cell cycle 
and apoptosis (32).   
 
Another well known signaling pathway involves the Nuclear Factor Kappa-light-chain-
enhancer of activated B cells (NFκB) transcription factors. This signal transduction 
cascade can be activated as a response to inflammation, UV radiation and other types of 
stress factors, ultimately leading to the transcription of more than 100 different genes, 
some important in proliferation and apoptosis (19;33). 
 
The Phosphoinositide 3-kinases (PI3Ks) signaling pathways, involve the activation of 
Akt, a serine/threonine kinase involved in the regulation of multiple components of the 
cell cycle, as well as promoting cell survival (19). The pathway is negatively regulated by 
a tumor suppressor protein, PTEN, which is commonly mutated in melanomas. In the 
absence of PTEN, the signaling pathway is constitutively active, thus leading to increased 
cell survival. PTEN is also a positive regulator of the pro-apoptotic protein p53, hence 
melanomas lacking PTEN may avoid apoptosis and cell cycle arrests (34). 
 
1.2.4 Cell death  
 
A cell can die in several ways, triggered by a variety of mechanisms. Different types of 
cell deaths are classified based on a variety of criteria; morphological-, enzymological-, 
functional- or immunological characteristics (35). Based on morphological changes, cell 
death can be divided into;  Apoptosis, Autophagy, Necrosis, Mitotic Catastrophe (36). 
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Figure 5. Morphological changes associated with apoptosis, necrosis and mitotic 
catastrophe 
 
1.2.4 Apoptosis 
 
The size of a population of cells is determined by the balance between cell division and 
cell death. Central in this is apoptosis, an active process of programmed cell death, 
important in development, differentiation, proliferation, tissue homeostasis and in the 
removal of defect cells (37).  
Apoptosis can be distinguished from other forms of cell death by its morphological 
characteristics, such as; cell shrinkage, membrane blebbing, chromatin condensation, 
cytoplasmic shrinkage, and at later stages, formation of apoptotic bodies (Figure 3). In 
addition, phosphatidylserine (PS) is exposed on the cell surface, sending out a signal to 
macrophages to engulf the dying cell, a mechanism designed to protect the nearby tissue 
from being affected by the cell death (38).  
Several mechanisms can lead to the activation of apoptosis in the cell; binding of death 
ligands, intracellular stress, loss of cell anchorage, lack of growth factors, and DNA 
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damage. Depending on the trigger, apoptosis will be initiated through an intrinsic- or/and 
an extrinsic pathway (38) (Figure 5). 
 
Figure 6. An overview of some of the components of apoptosis.  
 
The intrinsic pathway 
Intracellular stress signals can initiate apoptosis through the mitochondrial outer 
membrane permeabilization (MOMP), a process carefully regulated by the Bcl-2 protein 
family.  
The Bcl-2 proteins all share a sequence homology within conserved regions; the Bcl-2 
homology (BH) domains. The Bcl-2 proteins contain 1-5 BH domains, which are 
required for binding to other members of the family. Most (but not all) of the pro-
apoptotic Bcl-2 proteins (e.g. Bim, Bad, Bid) contain only one BH domain, these proteins 
are essential in sensing apoptotic signals, and will, if evoked, work to shift the balance 
between the multi BH domain anti-apoptotic proteins (e.g. Bcl-2, Bcl-xl, Mcl-1) and the 
pro-apoptotic proteins towards apoptosis (39). Although the exact mechanisms of 
cytochrome c release by the Bcl-2 family remain somewhat debated, it is thought that the 
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pro-apoptotic members of the Bcl-2 family activate Bak and Bax, which upon several 
conformational changes and oligomerization, can form pores in the mitochondrial 
membrane (40). The following drop in mitochondrial membrane potential (ΔΨm), leads to 
the release of pro-apoptotic proteins, such as cytochrome c and SMAC/DIABLO.  
Once released in the cytoplasm, cytochrome c forms a complex (apoptosome) with Apaf-
1 and pro-caspase 9. The apoptosome can, through cleavage, activate caspase 9 from its 
zymogen form (41).Caspase 9 is an initiator caspase which is capable of activating the 
effector caspases (caspase 3 and caspase 7), enzymes important in executing apoptotic 
changes in the cell.  
The release of SMAC/DIABLO from the mitochondria further boosts the apoptotic 
machinery by antagonizing the members of the Inhibitors of Apoptosis (IAP) family, and 
thereby inhibiting them. The IAPs (e.g. survivin, livin, xiap) are anti-apoptotic proteins 
which are thought to inhibit apoptosis by a direct binding to effector caspases, thus 
preventing their activations (42). 
 
Many stress signals can regulate the members of the Bcl-2 family, causing an activation 
of the intrinsic pathway of apoptosis.   
Oncogenic stress, such as DNA damage, can lead to stabilization and accumulation of 
p53, a tumor suppressor protein that can act as a transcription factor causing an increase 
of pro-apoptotic bcl-2 members, as well as mediating repression of anti-apoptotic bcl-2 
proteins. p53 may also bind directly to the mitochondria causing MOMP (43). Depending 
on the inducer of p53, a variety of responses have been detected, such as apoptosis, cell 
cycle arrest, diffentiation, senescence and DNA-repair (44). 
The transcription factor Nuclear ophan receptor protein (Nur77/TR3/NR4A1) can, if 
induced by certain death stimuli, translocate to the mitochondria where it transform Bcl-2 
to a pro-apoptotic protein, thereby causing release of cytochrome c, or it can target the 
endoplasmatic reticulumn (ER) thus promoting release of Ca2+, in both cases initiating 
apoptosis (43;45).  
 
The Bcl-2 members have also been reported to play a role in the induction of apoptosis 
by releasing Ca2+ from the ER, which in turn can lead to the release of pro-apoptotic 
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proteins from the mitochondria, as well as activating cytosolic kinases important in 
apoptosis (46).  
ER stress has, in addition, been shown to induce apoptosis and cell cycle arrest through 
the release of C/EBP homologous protein (CHOP/GADD153) (47). 
 
The extrinsic pathway  
Apoptosis can also be initiated through signals from the outside of the cell. Death ligands 
(such as TRAIL, Fas and TNFα) may bind to certain receptors on the cell surface, thus 
activating them. Activated death receptors will cluster together, and recruit adaptor 
proteins (e.g. FADD and TRADD), as well as procaspase- 8 or/and 10, forming a so 
called Death Inducing Signaling Complex (DISC) (48). Due to the close proximity of the 
proteins at the DISC, the initiator caspases (caspase 8 and caspase 10) get activated 
through autoprotolytic cleavage. The caspases can now detach from the DISC, and 
perform their proteolytic activities by activating the effector caspases and Bid. The 
cleaved pro-apoptotic Bcl-2 member Bid can crosstalk with the intrinsic pathway by 
activating Bax and/or Bak, thus enhancing the apoptotic effect (49). 
 
Caspase-independent apoptosis 
Apoptosis-like cell death has been reported to occur, independent of caspase activation. 
In the case of Caspase Independent Cell Death (CICD), the morphology of the dying cell 
will be similar to the apoptotic cell, although some of the characteristics may be slightly 
deviating, depending on the cell type and the initiating stimulus (50). Initiation of CICD 
can follow the activation of a death receptor (necroptosis), or occur through the intrinsic 
pathway by the action of proteins such as SMAC/DIABLO and Apoptosis inducing factor 
(AIF) (50;51).  
 
1.2.5 Necrosis 
 
Necrosis is a form of cell death thought to be less controlled than apoptosis. It is often 
associated with an inflammatory response in the nearby tissue as a reaction to the release 
of intracellular material from the dying cell. Death by necrosis can occur due to cellular 
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trauma, such as infection or ischemia, but has also been seen as a consequence of a death 
signal (52). 
The morphological changes seen in necrotic cells can be described as; swelling of the 
cell, loss of membrane integrity, and as a response to this; leakage of intracellular 
material to the surroundings (Figure 3). 
 
1.2.6 Mitotic catastrophe 
 
It is debatable whether mitotic catastrophe can be classified as a separate form of cell 
death, or if it is just a process leading to death, either through apoptosis or necrosis. 
Mitotic catastrophe is associated with deficiencies in cell cycle checkpoints, resulting in a 
divergent mitosis and thus aberrant chromosome segregation and excess amounts of 
DNA (53). 
The changes in morphology in the cell undergoing mitotic catastrophe will usually 
include; enlargement of the cells size, uncondensed chromosomes with deviations in the 
mitotic spindle, as well as the occurrence of micro-nuclei (Figure 3).  
 
1.2.7 Cell cycle  
 
The cell cycle is a series of events leading to division of a cell. Cell division is important 
both during development, as well as to balance up for dying cells in a tissue.  
In eukaryotic cells, the cell cycle consists of four distinct phases; Gap 1 (G1), Synthesis 
of DNA(S), Gap 2 (G2) and Mitosis (M) (Figure 5).The directional, ordered events of the 
cell cycle start in G1, a phase where the cell produces proteins and grows in size. In the 
following S phase, the cell synthesizes a new set of DNA. During the proceeding gap 
phase, G2, the cell expands and produces new proteins needed for mitosis, in particular 
proteins that will work as building blocks for the microtubules. The mitosis can itself be 
divided into an ordered series of events, ultimately leading to the physical division of the 
cell into two identical daughter cells. The new cells can proceed to a new round of the 
cell cycle, or they can enter the non-proliferative state G0. Cells can remain in the G0 state 
indefinitely, or they can re-enter the cell cycle at a later stage if needed (24). 
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The cell cycle is a tightly regulated process where each transition between phases 
requires the hetrodimerization of two molecules; cyclin (regulatory unit) and cyclin-
dependent-kinase (CDK) (catalytic unit). The levels of CDKs remain relatively constant 
throughout the cell cycle; their activity is regulated through phosphorylations and 
dephosphorylations. The concentration of the different types of cyclins, on the other 
hand, will vary in response to molecular signals that causes their synthesis and 
destruction (54). The cyclin-CDK complex formation thus have a timed appearance, 
giving rise to three main groups of complexes, G1 cyclin-CDK, S cyclin-CDK and 
Mitotic cyclin-CDK, specific to the phase they occur (55). The transitions between 
different phases of the cell cycle are regulated by the synthesis and destruction of cyclins, 
as well as through the activation of CDKs.  
 
 
Figure 7. A simplified overview of the eukaryotic cell cycle, its check points and some 
of its key regulators, with emphasis on the G1/S transition. 
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The cell cycle is further regulated by a series of checkpoints dispersed throughout the 
cycle, its three main control points being the G1/S-, S- and G2/M checkpoints (Figure 5). 
At each checkpoint, surveillance mechanisms in the cell make sure that a transition is not 
initiated before the previous stage is completed (24). The G1/S checkpoint is also known 
as the restriction point (R), a transition site where the cell evaluates both its external and 
internal environment before committing to a new round of the cell cycle.  
 
Transition through the G1/S checkpoint requires the inactivation of the retinoblastoma 
protein (pRb). Whilst in a hypophoshorylated state, pRb is active and bind E2F, a 
transcription factor necessary for the expression of genes needed for entry to the S phase 
(56). Cyclin D/CDK4/6 and Cyclin E/CDK2 act cooperatively to inactivate pRb through 
phosphorylation, by so releasing E2F, allowing the cell cycle to progress (57). 
  
Regulation of the cell cycle is also conducted by two families of CDK inhibitory proteins 
(CKIs); the INK4 - and the CIP/KIP family.  
The inhibitory proteins of the INK4 protein family include p14 INK4d (p14), p15 INK4b 
(p15), p16 INK4a (p16) and p18 INK4c (p18). These are proteins which can bind to CDK4 
and/or CDK6 in the G1 phase,  thus inactivating the cyclin-CDK complexes and arresting 
the cell cycle (58).  
The CIP/KIP family consists of three members; p21Cip1/WAF (p21), p27Kip1 (p27)and 
p57Kip1(p57), that can inhibit the cell cycle through binding to CDKs, by so inactivating 
the cyclin-CDK complex, causing a subsequent cell cycle arrest .   
 
The tumor-suppressor protein, p53 also plays an important role in regulating the cell 
cycle, by being a central regulator at the G1/S and the G2/M checkpoints (59). p53 may 
increase the transcription of p21, thus arresting the cell cycle (60). 
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1.2.8 Retinoids 
 
Retinoids are a family of proteins comprising synthetic and natural vitamin A derivatives 
and analogues, known to regulate many biological processes including growth, 
differentiation, metabolism, apoptosis, morphogenesis and homeostasis (61).  
 
The effects of the natural retinoids (RA) are thought to be mediated mainly through their 
binding to nuclear receptors, retinoic acid receptors (RARs) and retinoid X receptors 
(RXRs), each consisting of three different proteins (α, β and γ) ( Figure 6) (62). The 
retinoid receptors can in turn dimerize and bind to specific response elements (RAREs or 
RXREs) found in the promoter regions of DNA, ultimately leading to a change in the 
cells gene expression. Whereas the RARs can only be activated through the dimerization 
with other RARs and RXRs, the retinoid X receptors may dimerize with other molecules, 
such as orphan nuclear receptors, for instance Nur77 (63). 
 
Less is known about the pathways used by the synthetic retinoids, their effects on 
apoptosis and differentiation have been shown to be only partially mediated through their 
binding to the retinoic receptors (8). 
 
 
Figure 8. Receptor mediated effects of retinoic acids 
 
Studies on the effects of the natural retinoids can be dated all the way back to 1925 (64), 
and has over time led to the discovery of their anti-tumor qualities. Natural retinoids 
(such as ATRA) are now included in some cancer treatments, for instance in patients with 
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promyelocytic leukemia (APL) showing a >90% complete remission (3). Despite these 
promising results, the natural retinoids have had limited effects in other tumors, as well as 
causing  hepatic toxicity in the treated patients due to the high doses needed for treatment 
(65;66). 
The recent studies on the anti-tumor effects of retinoids have therefore been more 
concentrated on developing synthetic retinoids, associated with less toxicity and higher 
efficiency.       
 
1.2.9 CD437  
 
Synthetic Retinoid 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene Carboxylic 
Acid (CD437/AHPN) has been proposed as a chemopreventing agent, showing promising 
results in vitro. CD437 has been reported to induce growth arrest and/or apoptosis in 
melanoma cells (5), as well as in ovarian- (67) -, breast (68) -, gastric (69)-, and non-
small-cell-lung cancer (70), as well as leukemia (71). 
 
 
Figure 9. Molecular structure of CD437 
 
CD437 has been shown to have selective apoptotic activities. In addition, it is a strong 
apoptotic inducer associated with less toxicity than the natural retinoids, for instance 
ATRA (5;72). 
 
1.2.10 CD437s effect on apoptosis; previous studies  
 
The mechanisms through which CD437 induces apoptosis are diverse, and may vary a 
great deal between different types of cells. 
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It has been demonstrated that CD437 can induce apoptosis in cells lacking nucleus, 
indicating that transcriptional activities are not a requirement (73). 
Other studies have, on the other hand, shown CD437-induced apoptosis to be directed 
through the activation and up-regulation of  certain transcriptional factors, such as AP-
1(7) and c-myc (74). 
To further complicate the puzzle, CD437 can trigger apoptosis through the endoplasmatic 
reticulumn (ER) in some cell types (45;75), whereas in others, apoptosis may be induced 
through the mitochondria (73;76), or through a lysosomal pathway (71). CD437-induced 
apoptosis may be dependent on caspase activation (77) , or it may be induced in a 
caspase-independent manner (78). 
Induction of apoptosis by CD437 has been reported to be partially attributable to its 
binding to the natural retinoid receptors (RARγ) in some cells (66), whereas it may 
happen in a RAR-independent mechanism in others (8;9). 
Treatment with CD437 has also been shown to mediate apoptosis through the 
translocation of the orphan nuclear receptor Nur77 from the nucleus to either the ER 
(45;79) or to the mitochondria (80-83).  
 
Many signalling pathways have been suggested to play a role in CD437 induced 
apoptosis in cancer cells. Studies have revealed that CD437 can trigger apoptosis through 
activation of the p38/MAP kinase pathway (67;84), the JNK/MAP kinase pathway 
(30;84), the ERK1/2/MAP kinase pathway (82), the NFκB pathway (5), or through down-
regulation of the Akt signaling pathway (85).  
In addition, CD437 has been shown to cause double-strand breaks in DNA, leading to 
p53 activation and apoptosis (86).  
Other reports have pointed to the translocation of Nur77, to either the ER, mitochondria 
or the nucleus, as a mechanism through which the retinoid triggers apoptosis 
(45;82;84;87). 
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1.2.11 CD437s effect on the cell cycle; previous studies 
 
Previous studies have shown that CD437 can cause cell cycle arrest, the nature of the 
arrest seem to be cell-line dependent (10;88-92).  
A G0/G1 arrest was observed in human lung cancer cell lines. An elevation of the cell 
cycle inhibitor protein p21 was suggested to be critical for the cell cycle arrest, which 
occurred through a p53-independent mechanism (93). In human epidermal keratinocytes, 
CD437 was also reported to induce a G1 arrest (89). 
In prostate carcinoma cell lines, S-phase arrest has been observed following treatment 
with CD437, accompanied by elevated levels of E2F and increased degradation of cyclin 
B1 (88).  
Studies on teratocarcinoma cell lines have shown that CD437 can cause a G2/M cell cycle 
arrest, through a RAR-independent pathway (10).  
 
2. Materials and methods 
 
All reagents and materials described are listed under ‘8. Appendix’ 
 
2.1 Cell culture 
 
The human melanoma cell lines, FEMX1 and WM239 have been used for all the 
experiments described in the master thesis.  
The FEMX1 cell line originates from a lymph node metastasis in a patient with malignant 
melanoma, which was removed at the Norwegian Radium Hospital in Oslo. It was first 
implanted into a mouse, and grown as a xenograft cell line. These cells were later 
collected and grown in vitro as a continuous cell line; FEMX. The re-injection of FEMX 
cells into a nude mouse, have given rise to a new cell line called FEMX1. 
The WM239 cell line was established by Meenhard Herlyn, The Wistar Institute, 
Philadelphia, USA, in 1981. This melanoma cell line originates from a metastasis, and is 
used with the kind permission from the Wistar Institute. 
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In order for the cells to grow in vitro, several factors have to be optimized to keep the 
conditions similar to the natural habitat of the cells in vivo. These are factors such as 
temperature, proportions of CO2, growth factors and nutrition. The growth medium 
contains nutrients for the cells, ensures a correct pH balance, and provides the cells with 
external growth factors. 
In order to keep the cell growth from becoming too dense (may cause premature aging in 
the cells), and to stop waste from the cells from building up, the cells must be split at 
regular intervals.  
 
Both cell lines were maintained in RPMI-1640 media, containing 5% Fetal Calf Serum 
(FCS) and 2mM L-glutamine. The cells were incubated in a Sanyo CO2 incubator with a 
temperature of 37°C, and humidified air containing 5% CO2. The media were shifted and 
the cells split every 3rd day, after having reached a confluence of approximately 70-80%.  
 
In order to split the cell culture, a mixture of Trypsin/EDTA (TE-buffer) was used to 
detach the cells. The old medium was first removed, and 2 ml TE-buffer added 
and removed, leaving a thin liquid film. The cells were then incubated at room 
temperature for approximately 2 minutes, whilst the cell bottle was tapped to 
mechanically loosen the cells.  
 
2.1.1 Treatment with CD437 
 
The synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic 
acid (CD437) was purchased from Sigma-Aldrich™ at a stock concentration of 10mM, 
and diluted to 100µM in Dimethyl sulfoxide (DMSO) prior to the experiments.  
 
When the cells were treated with CD437 for a maximum of 24 hrs, cells with a 
confluence of 60-70% (approximately 5x106 cells) were split 1:2 a day in advance of the 
experiment. Prior to the longer lasting experiments (48 hrs and 72 hrs), cells were plated 
out a day in advance with respectively 7x105 and 5x105 cells.  
The medium was preheated (37ºC) prior to all the experiments.  
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The FEMX1- and WM239 cell lines were treated with CD437 dissolved in DMSO 
(0.1µM or 1µM), for various time intervals (1, 3, 8, 24, 48 and/or 72 hrs). In addition, 
control cells, treated with DMSO alone, were given the same conditions as the cells 
treated with CD437, and harvested along with each experiment. 
 
2.1.2 Preparation of protein lysate 
 
Cells were harvested for protein analysis by gently scraping the bottle using a rubber 
policeman. The cell suspension was then centrifuged for 5minutes at 12000rpm in a cold 
centrifuge (4ºC). The medium was discarded, and cold PBS was added to wash the cells. 
The suspension was centrifuged, and the PBS removed. Newly prepared lysisbuffer 
(~100μL per sample, depending on the pellet size) (6. APPENDIX) was added to the cell 
pellet. The suspensions were sonicated to further lyse the cells and thus liberate the 
proteins. 
 
2.1.3 Measurement of protein concentration 
 
The protein sample (5μL) was diluted in 495μL H2O. From this suspension 100μL and 
200μL were mixed with respectively 700μL and 600μL of 1:100 lysis buffer. Bradford 
(200μL) was added to each of the protein dilutions. The optical density was measured at 
595nm by the use of a Perkin Elmer Lambda EZ201 spectrometer. The protein 
concentration was then determined by the use of a pre-made standard curve.   
 
2.2 Western blot 
 
Protein lysates (50µg) from each sample were mixed with lysisbuffer and 6x loading dye 
to a total volume of 25µL each. The protein samples were further denatured by heating 
them for 3 minutes at 100ºC. Samples were then transferred on to a 12% Sodium Dodecyl 
Sulphate - polyacrylamide gel (SDS-PAGE), along with a commercial Full-range 
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RainbowTM coloured molecular weight marker. The marker was added to one of the wells 
on the gel for the purpose of later comparing protein sizes. 
The gel was set to run for approximately 3 hrs at 30mA/300V, in running buffer. The 
SDS-PAGE electrophoresis separates the denatured proteins based on their 
electrophoretic mobility. SDS binds to the proteins, giving them a negative charge. Once 
an electric field is applied to the gel, the proteins will migrate towards the anode. Shorter 
proteins will travel through the pores of the gel at a higher pace, whereas proteins with a 
higher mass will meet more resistance. Proteins of different sizes are thus separated. 
The proteins from the gel were transferred onto a methanol-activated Immobilon-PVDF 
membrane, by blotting it in a wet transfercell (Bio-Rad Trans-blot DF) over night at 
14mA/21V, in transfer buffer. The electric current is used to pull the proteins from the 
gel and on to the membrane. A solution of Naphtol-Blue- Black was used to stain the 
total protein content on the membrane to control for even loading.To block for unspecific 
bindings of antibodies, the membrane was incubated for 1 hr at room temperature, in 
TBS, 0.05 % - 0.25% Tween-20 with 5% w/v nonfat dry milk (TBST concentration 
depended on the primary antibody that was later used, see appendix). The membranes 
were then incubated with a primary antibody dissolved in either milk or BSA, and left on 
a shaker overnight at 4ºC. The membrane was washed 3x10minutes in TBST, before 
adding an appropriate HRP-linked secondary antibody (6.2 Antibodies used for western 
blot). Hybridization was allowed for ~ 45minutes at RT. The washing procedure was 
repeated. In order to detect proteins, the membrane was incubated at RT for 5minutes 
with ECLplus reagent (Amersham), and exposed using a film (Kodak). Horseradish 
peroxidase (HRP) from the secondary antibody catalyses light emission from the 
oxidation of luminol (ECLplus reagent).The emitted light was then detected on a film, 
and developed by the use of an AGFA Curix 60 photo developer.  
 
2.3 Cell counting by the use of trypan blue 
 
Dead or dying cells can be distinguished from living cells based on the uptake of trypan 
blue added to the medium. The cell membrane of the dying cell will be permeable to the 
dye, whereas uptake will not occur in the living cells.   
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To assay the amount of dead or dying cells, FEMX1 and WM239 cells were dyed using 
trypan blue, after treatment with 1µM CD437 for 24, 48 and 72 hrs. Cells not treated with 
CD437 were used as control. 5x104cells per well were seeded in 24-well-plates, one day 
in advance of the treatment (control cells to be grown for 48/72 hrs were seeded 
2x104cells per well). After the respective treatment, cells were detached using 
trypsin/EDTA and collected along with the medium containing floating cells. The cell 
suspensions were centrifuged for 5minutes at 1200rpm, and the supernantant discarded. 
PBS was used to dilute the cells to a total volume of 500µL, before adding 50µL trypan 
blue (0.4% trypan blue in PBS). Both viable and trypan blue cells were counted, using a 
Bürker counting chamber.   
 
2.4 CellTiter 96® AQueous Non-Radioactive Cell Proliferation 
Assay (MTS) 
 
The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium)(MTS) method is based on a colorimetric principle that can be used to 
determine the percentage of viable cells. Viable cells contain active enzymes that can 
reduce MTS in the presence of phenazine methosulfate (PMS) into formazan, a water 
solvable molecule giving of a brown color that can be measured at 490nM. The amount 
of produced formazan is directly proportional to the number of living cells in the culture.  
The MTS assay was used to measure a possible response in cell viability, with regards to 
various doses (µM) - and length of exposure (hrs) to CD437.  
FEMX1 and WM239 were plated out at 5000 cells per well in 96well plates, and left to 
grow overnight. RPMI-1640 medium containing CD437 in DMSO was added to the cells, 
giving a desired concentration, DMSO alone was added to the control cells. To correct 
for the signal from RPMI-1640 medium was added to the empty wells on the plates. After 
a certain length of time, depending on the purpose of the assay, 40µL CellTiter 96® 
AQueous One Solution, was added to each of the wells. The plates were set to incubate for 
approximately 1,5hrs, before measuring the absorbance at 490nm using ASYS UVM340 
96-well plate reader. 
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2.5 Flow cytometry 
 
Flow cytometry is a method where microscopic particles in suspension, such as cells and 
DNA, are counted and examined by passing them by an electronic detection apparatus 
(Figure 11). Traits such as a cell’s complexity (side scattered light), size (forward 
scattered light) and fluorescence can be measured by the surrounding detectors, as the 
cell is passed through a light beam. The method can be used to measure fluorochromes 
attached to desired molecules in a cell (such as DNA or proteins). The fluorescens 
labelled molecules will emit light when excited with a laser beam with of a suitable 
wavelength (depending on the fluorochromes used). The emitted light will thus be 
proportional to the amount of labeled molecules in the cell. 
The Terminal Transferase dUTP Nick End Labeling (TUNEL) is such a method for 
measuring fragmentation of DNA in a cell, a feature associated with apoptosis. An 
enzyme called Terminal deoxynucleotidyl transferase (Tdt) catalyzes the addition of 
dUTP where there are nicks in the DNA. A secondary marker (such as streptavidin-FITC) 
can again be used to label the dUTPs.  
Fluorscent labelling can also be used to measure a cell’s total amount of DNA, by stains 
such as Hoechst.  
 
 
 
 
 
 33
 
Figure 11. The flow cytometer 
A beam of light of a desired wavelength is sent through single cells in suspension. 
Surrounding detectors gathers information about the cell through detecting the scattered- 
and emitted light (94).  
 
Cells were treated with 1µM CD437 or DMSO, and fixated in methanol after 24, 48 and 
72 hrs of treatment. The cells were then washed 3 times in PBS, before adding 100μL 
newly prepared Tdt-solution to each sample (appendix). The Tdt-solution was left to 
work for 30 minutes, whilst the samples were incubated at 37ºC. The cells were then first 
washed once in PBS, before repeating the washing procedure twice using 0.1% Triton 
TX100 PBS. Trition TX100 in PBS was used for permeabilization of the cells prior to the 
immunostaining. Next, 100μL newly prepared Streptavidin-solution (appendix) was 
added to each sample. The cells were left to incubate at room temperature for 1 hr, whilst 
being sheltered for light. After the incubation, the cells were washed once in 0.1% Triton 
TX100 in PBS, before adding 500μL newly prepared Hoechst 33258 solution (appendix). 
Hoechst staining was allowed to occur for 30 minutes, whilst the cells were kept on ice 
(4ºC). Aggregates of cells were removed by filtration. All samples were kept on ice 
before being analyzed by the use of a LSR II UV laser flow cytometer. 
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2.6 Transient transfection with SiRNA 
 
Transfection is a non-viral method for introducing foreign nucleic acids into a eukaryotic 
cell, such as small/short interfering RNA (siRNA). These are short double stranded RNA 
oligonucleotides consisting of 21-23bp, that for instance are involved in the RNA 
interference (RNAi) pathway. RNAi makes use of a natural defense mechanism in the 
cell, designed to protect against virus and transposons. The principle behind RNAi can be 
used to study the role of a protein of interest, by deliberately shutting down its expression 
by the use of designed sequences siRNA (95).    
 
 
 
Figure 10. The main mechanisms behind RNA interference (RNAi) 
A cytoplasmic ribonuclease, Dicer, cleaves a siRNA from a specific sequence of dsRNA. 
The siRNA attracts a complex of molecules called RISC. The catalytic compontent, 
Argonaute, causes the degradation of one of the strands in the siRNA. The RISC/siRNA 
complex can now recognise and bind to mRNA complementary to the siRNA, which the 
RISC can cleave (adapted from (95)) .      
 
For the purpose of knocking down Nur77 (NR4A1), a transfection was performed using 
siRNA. Transfection was carried out using the Lipofectamine™ RNAiMAX method, a 
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commercially available reagent which alters the plasma membrane of the cells, making 
them more susceptible for taking up nucleic acids from the surrounding medium (96). 
Cells (FEMX1 and WM239) were seeded (1.5x104 cells per well) in 6-well-plates a day 
in advance of the transfection.   
The following day, master mixes were prepared containing either siNR4A1 (with the 
target sequence; 5’GAGGAGAGAGCUUCCAUGCCUA3’) or siCTR (containing a non-target 
sequence; 5’GAGGAGAUCGACUUAGUACCGGCUA3’) mixed with lipofectamine™RNAiMAX and 
Optimem®I. The master mixes were prepared according to the manufacturers protocol, 
giving a total concentration of 100nM siRNA per well. The cells were incubated for 48 
hrs, and were then treated with 1μM CD437 for 24 hrs. The transfection efficiency was 
later tested by western blot analysis. 
 
3. Results 
 
3.1 Treatment with CD437 has an antiproliferative effect on 
FEMX1 and WM239 cells 
 
It has previously been shown that CD437 has an antiproliferative effect in a number of 
cancer forms (97). To investigate whether CD437 can inhibit proliferation in FEMX1 and 
WM239, cells were treated with the retinoid and visually compared to control cells after 
24, 48 and 72 hrs (Figue 12).  
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Figure 12. Antiproliferative effect of CD437. 
FEMX1 and WM239 cells were allowed to attach and grow for 24 hrs before treatment 
with 1µM CD437. The antiproliferative effects of CD437 were monitored at 24, 48 and 
72 hrs of treatment, using a light microscope with 5x magnification. 
 
Fewer cells were seen after treatment with CD437 in both cell lines, compared to the 
control cells. Furthermore, the difference got more pronounced after longer exposure. 
FEMX1 was seeded with a lower cell density than WM239 due to its rapid growth 
(Figure 12).  
 
In order to quantify the effect of CD437, both treated and untreated cells were counted. 
To ensure that only living cells were included, dead cells were stained with trypan blue 
and could thus be excluded from the count.  
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Figure 13. CD437s effect on proliferation in FEMX1 and WM239 cells.  
The cells were seeded in 24 well plates, and left to attach and grow for 24 hrs in advance 
of the treatment with 1μM CD437. Living cells were counted using a Bürker counting 
chamber, whilst excluding dead cells dyed with trypan blue. The amounts of living cells 
are plotted as percentages of seeded cells at 24, 48 and 72 hrs of treatment with CD437. 
The data are expressed as the mean of three independent biological experiments, with 
error bars showing standard deviation.  
 
The results from the cell count were compatible with the results from the microscopical 
evaluation. In both FEMX1 and WM239, the control cells continued to proliferate whilst 
the treated cells staggered. The difference became apparent after 48- and 72 hrs, showing 
no overlaps in standard deviations of the control- and treated cells. After 72 hrs there 
were approximately 450% and 900% more control cells than originally seeded, whereas 
in the treated samples there were fewer cells (~70% and ~80%), in FEMX1 and WM239 
respectively.   
FEMX1 control cells appeared to proliferate approximately twice as fast as the WM239 
control cells. 
 
3.2 The effect of CD437 on cell viability is dosage- and duration 
dependent 
 
To assess the abilities of CD437 to affect cell viability, in regards to duration and dosage 
of the treatment, an MTS analysis was performed. 
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Figure 14. Treatment with CD437 reduces the amount of viable cells in a dosage (A) - 
and time (B) dependent manner.  
Five thousand cells were seeded per well in 96 well plates, and allowed to attach and 
grow for 24 hrs before treatment with CD437 or DMSO (control cells). An MTS analysis 
was used to determine the amount of viable cells. The changes in viability of the treated 
cells are presented as percentage of control cells. Data are expressed as the mean of 
three independent biological experiments, with error bars showing standard deviation.  
 
Both cell lines exhibited a dosage-dependent reduction of viable cells after treatment with 
CD437 for 24 hrs. The FEMX1 cell line displayed a larger relative reduction of viable 
cells than WM239 cells, when exposed to CD437. Treatment with 0.1μM and 1μM for 24 
hrs resulted in relative reductions of respectively none and 41% in FEMX1, and 8% and 
25% in WM239 (Figure 14A). 
When treated with 1μM CD437, both FEMX1 and WM239 showed a stronger relative 
reduction of viable cells when exposed for longer periods of time. The reduction was 
more profound in FEMX1, than in WM239. Treatment with 1μM CD437 for 24 and 72 
hrs resulted in a relative reduction of respectively 45% and 77% in FEMX1, and 21% and 
54% in WM239 cells (Figure 14B). 
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3.3 CD437 promotes G1 and S-phase arrest 
 
It can not be concluded from the MTS data whether the reduction in cell viability is due 
to an increased cell death and/or cell cycle arrest. To further investigate the effects of 
CD437, a flow cytometry analysis was performed to determine the impact on cell cycle 
distribution.   
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Figure 15. Treatment with CD437 induces S-phase arrest in FEMX1 (A) and G1 arrest 
in WM239 (B) cells. 
The cells were seeded in 75cm2 bottles, and left to attach and grow for 24 hrs in advance 
of treatment with 1μM CD437 dissolved in DMSO, or DMSO alone (control cells). The 
cells were harvested after 24, 48 and 72 hrs exposure. The cells were counted (y-axis) in 
regards to their DNA content (labeled with Hoechst, shown on the x-axis), by the use of 
flow cytometry. The data presented are representative for the three individual biological 
experiments that have been conducted.   
 
The treated cells contained fewer cells than the control cells, a difference attributable to 
the antiproliferative effects of CD437 previously shown. The graphs of the cells treated 
with CD437 are thus more ragged than those showing the control cells. In order to find 
the exact location of the distribution peaks in the treated cells, mixtures containing both 
untreated- and treated cells were analyzed.  
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The results from the flow analysis showed that FEMX1 cells have been arrested in the S-
phase of the cell cycle. CD437 appear to arrest FEMX1 in G1/S phase after 24 hrs of 
treatment, whereas the S-phase arrest became apparent after 48 and 72 hrs.  
Treatment with CD437 caused a G1-arrest in WM239; the arrest was evident after 24, 48 
and 72 hrs. 
 
Western blot analysis was used to further evaluate the effect of CD437 on the cell cycle 
by assessing the expression of various associated proteins.  
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Figure 16. Effects of CD437 on the expression of cyclins (A) and some of the 
regulators of the cell cycle (B) in FEMX1 and WM239. 
The cells were seeded in 75cm2 bottles containing RPMI 1640 media with 5%FCS / 2mM 
L-glutamine, and left to attach and grow for 24 hrs in advance of  treatment with 0.1μM  
or 1μM CD437. Control cells were treated with DMSO alone, and given the same 
conditions as the cells exposed to CD437. Protein lysates were prepared as described 
under ‘2.0 Methods’. Western blot analysis was used to evaluate the effect of CD437 on 
protein expression.  Representative loading controls (α-tubulin) have been enclosed. The 
data presented have been reproduced at least three times through independent 
experiments, yielding the same pattern. 
 
Since it is well documented that the total protein level of cyclin dependent kinases 
(CDKs) remains relatively constant throughout the cell cycle, these proteins have not 
been tested (54). 
In FEMX1 cells, a substantial increase of cyclin E and a marginal increase in cyclin A 
were seen after 24 hrs of treatment with 1μM CD437. Moreover, whereas a reduction in 
the cyclin D1 level was observed, the level of cyclin D3 remained unaffected. There were 
no changes in the expression pattern of any of the examined cyclins in WM239 cells.  
Treatment with 1μM CD437 led to a prominent increase of p21 and p53 in both cell lines, 
whereas the protein expression of p27 was unaltered. 
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3.4 Treatment with CD437 causes cell death in FEMX1 and 
WM239 cells 
 
Studies have shown that CD437 can cause cell death, allegedly apoptosis, in a variety of 
cell lines (1;5-8). To examine the retinoid’s death promoting abilities, dead cells were 
stained with trypan blue. Both dead/dying- and living cells were counted using a Bürker 
counting chamber.  
 
 
Figure 17. Effect of CD437 on cell death in FEMX1 and WM239 cells. 
The experiments were carried out as described under Figure (previous figure).  
 
CD437 caused cell death in both FEMX1 and WM239, the relative percentage of dead 
cells increased with prolonged exposure. Seventy-two hours of treatment with 1μM 
CD437 resulted in 45% and 37% dead cells in FEMX1 and WM239 respectively.  
 
3.5 Treatment with CD437 causes morphological changes in 
FEMX1 and WM239. 
 
In order to monitor the effect of CD437 on morphology, treated- and control cells were 
viewed by the use of a light microscope.  
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Figure 18. Effect of CD437 on cell morphology.  
FEMX1 and WM239 cells were allowed to attach and grow for 24 hrs prior to treatment 
with 1µM CD437. The morphological features of the cells were visualized after 72 hrs of 
treatment, using a light microscope with 32x magnification.  
 
Both cell lines showed morphological changes associated with apoptosis when treated 
with the retinoid. These changes included; expansion in overall cell size of some cells, an 
alteration in shape with an increase of pseudopodes (axon like arms going out from the 
cell bodies), as well as many small fragments floating around in the media. These 
fragments may be residues from dead cells (apoptotic bodies). Many smaller cells were 
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also seen (arrows), some showing signs of membrane blebbing and chromatin 
condensation. These cells were rounded up, and did no longer have pseudopodes.    
 
3.6 DNA fragmentation in WM239 cells after treatment with 
CD437 indicates ongoing apoptosis   
 
In order to assess whether the dead/dying cells found in the previous cell count were 
undergoing apoptosis, a TUNEL analysis was performed to determine DNA 
fragmentation. Fragmentation of DNA is a biochemical feature that can often be seen in 
apoptotic cells. Apoptosis might well happen without DNA fragmentation, hence this can 
not be used as an exclusive mean to define this type of cell death (35).  
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Figure 19. Effects of CD437 on DNA fragmentation in FEMX1 (A.) and WM239 (B.) 
cells. 
The cells were seeded in 75cm2 bottles, and left to attach and grow for 24 hrs in advance 
of treatment with 1μM CD437 dissolved in DMSO, or DMSO alone (control cells). The 
cells were harvested after exposure to the retinoid for 24, 48 and 72 hrs. Potential DNA 
fragmentation was assessed by the use of the TUNEL technique. DNA strand breaks were 
determined by measuring the incorporation of fluorescein-labeled dUTP (x-axis), relative 
to the overall DNA content of the cells (y-axis). Percentage of cells found to have DNA 
fragmentation has been enclosed on the individual figures. The data presented are 
representative for the three individual biological experiments that have been conducted. 
 
The TUNEL analysis gave no apparent increase of DNA fragmentation in FEMX1 cell 
after 24, 48, 72 hrs exposure to CD437. Fragmentation of DNA was on the other hand 
pronounced in WM239 after 72 hrs treatment with CD437, showing 55.4% of cells 
having DNA strand breaks. No prominent changes were seen in WM239 cells in regards 
to DNA fragmentation, when treated for shorter time intervals (24 and 48 hrs). 
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3.7 CD437 causes alterations in the expression of proteins 
involved in apoptosis 
 
To further investigate the intracellular mechanisms behind CD437 mediated cell death in 
FEMX1 and WM239, expression of selected proteins involved in apoptosis was 
investigated using western blot analysis.  
 
Caspases can be activated through cleavage from their inactive zymogen form, thus 
promoting apoptosis (98). Likewise, cleavage of PARP has also been reported as a 
marker for apoptosis (99).To investigate whether CD437 could cause caspase cleavage 
and/or PARP activation in FEMX1 and WM239, potential protein cleavage was 
examined using western blot analysis. 
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Figure 22. Effects of CD437 on caspases and PARP. 
The experiments were carried out as described under Figure 16).  
 
Cleavage of PARP, as well as caspase 8, -9 and -3, was found in FEMX1 cells treated 
with 1μM CD437. The WM239 cells showed cleavage of caspase 8, caspase 9 and 
PARP, after 24 hrs of treatment with1μM of the retinoid. No cleavage of caspase 3 was 
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detected in WM239. Treatment with the lower dosage, 0.1μM CD437, yielded no 
detectable changes in protein expression in either cell line (Figure 22). 
 
Activation of caspase 9 requires the release of cytochrome c from the mitochondria. The 
pro-apoptotic members of the Bcl-2 family are central in mitochondrial mediated 
apoptosis. Previous studies have shown that the expression of these proteins may be 
elevated as a response to treatment with CD437(76;100). 
 
 
Figure 20. Effects of CD437 on protein levels of some of the pro-apoptotic members of 
the Bcl-2 family. 
The experiments were carried out as described under Figure 16.  
 
No alterations in the overall protein expression were detected in any of the tested pro-
apoptotic members of the Bcl-2 family. Cleavage of Bid was not observed in either cell 
line.   
 
A reduction of the pro-apoptotic members of the Bcl-2 family may contribute to 
mitochondrial mediated apoptosis (39). In order to evaluate whether treatment with 
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CD437 could affect the expression of such proteins in FEMX1 and WM239, western blot 
analysis was again employed. 
    
Figure 21. Effects of CD437 on protein levels of some of the anti-apoptotic members of 
the Bcl-2 family.   
The experiments were carried out as described under Figure16.  
 
No major alterations in protein expression of the anti-apoptotic members of the Bcl-2 
family were detected in either cell line, post treatment with the retinoid.  
 
IAPs are known to inhibit both the initiator- and effector caspases in promoting apoptosis 
(101). Western blot analysis was conducted to determine whether treatment with CD437 
could affect the protein expression of IAPs in FEMX1 and WM239 cells.  
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Figure 23. Effects of CD437 on protein levels of some of the members of the IAP 
family. 
The experiments were carried out as described under Figure 16.  
 
Exposure to 1μM CD437 for 24 hrs caused a decrease in the expression of survivin in 
WM239 cells. No other prominent changes were seen. 
 
3.8 Signaling pathways are activated by CD437 in FEMX1 and 
WM239 
 
As described in the introduction chapter, previous studies have shown that CD437 can 
trigger several intracellular signaling pathways (1.2.10 CD437s effect on apoptosis; 
previous studies) leading to apoptosis and/or cell cycle arrest. In order to elucidate 
whether CD437 activates any of the previously described signaling pathways, western 
blot analysis was performed measuring the level of both the phosphorylated and total 
expression of some key proteins.  
Activation of signaling pathways may happen quickly after exposure to a ligand, hence 
the protein expression of various signaling molecules has been determined after 1, 3, 8 
and 24 hrs of treatment with CD437.  
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Figure 24. Effect of CD437 on the expression of a selection of key proteins involved in 
intracellular signaling in FEMX1 (A) and WM239 (B).  
The experiments were carried out as described under Figure 16. The cells were, however, 
harvested after 1, 3, 8 and 24 hrs treatment with CD437.  
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The overall protein expression of the signaling proteins has been enclosed, both as a 
loading control, but also to make sure CD437 does not affect the total expression of the 
protein.  
Some of the phosphorylated proteins were weekly expressed (pJNK and IκBα-p). To 
ensure that this was not due to technical problems; positive controls were enclosed during 
the western blot analysis (not shown). 
The results revealed an elevation in phosphorylated AKT after treatment with 1μM 
CD437 (1, 3, 8 and 24 hrs) in FEMX1. The level of activated p38 was marginally 
increased after 3 and 8 hrs and strongly increased after 24 hrs of exposure to 1μM 
CD437. No distinct alteration in protein expression could be detected in cells treated with 
0.1μM CD437.  These results indicate that treatment with 1μM CD437 has activated the 
PI3K- and the p38/MAPK signaling pathways in FEMX1 cells. 
CD437 appeared to activate only the p38 signaling pathway in WM239. Thus, Pp38 
expression was elevated after 3, 8 and 24 hrs of treatment with 1μM CD437. Treatment 
with lower concentration of CD437 (0.1μM), failed to produce any noticeable alteration 
in protein expression. 
 
3.9 CD437 causes an increased expression of transcription 
factors in FEMX1 and WM239 
 
Previous studies have revealed that CD437 alter the expression of transcription factors 
associated with proliferation and apoptosis (7;45;82;88;102). In order to elucidate 
whether exposure to CD437 can alter the expression of a selection of transcription 
factors, western blot analysis was performed. 
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Figure 25. Effect of CD437 on the expression of a selection of transcription factors in 
FEMX1 and WM239. 
The experiments were carried out as described under Figure 16. The cells were, however, 
harvested after 3 and 24 hrs treatment with CD437.  
 
In both cell lines increased protein expressions of Nur77, E2F-1 and p-c-jun were seen 
after 3 and 24 hrs treatment with CD437 (Figure 25).  
 
3.10 Preliminary results suggest silencing of Nur77 may affect 
the expression pattern of other proteins following treatment with 
CD437 
 
Treatment with CD437 resulted in an increase of the orphan receptor Nur77. A previous 
study suggests that CD437 induced apoptosis requires the expression of Nur77 (103). In 
order to study the effect of CD437 in the absence of Nur77, a siRNA transfection was 
performed to shut down its expression.  
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Figure 26. Effect of CD437 on the expression of various proteins, in the absence of 
Nur77.  
FEMX1 and WM239 were plated out at 5000 cells per well in 96well plates, and left to 
grow overnight. Transfections were carried out as described under ‘2.6 Transient 
transfection with siRNA’. Transfected- (SiNur77 or SiCtr) and control cells were allowed 
to transfect/grow for 48 hrs, before treatment with 1µM CD437/DMSO for 24 hrs. 
Protein lysates were prepared as described under ‘2. Methods’. Western blot analysis 
was used to evaluate the effect of CD437 on protein expression. Amido-Black staining 
has been enclosed as loading control. The data is preliminary. 
 
Transfection with siNur77 effectively shut down the expression of Nur77. In FEMX1 
cells treated with CD437, it appeared as the lack of Nur77 decreased the expression of 
p53 and E2F-1. No The WM239 cells, on the other hand, did not show any changes in 
protein expression following treatment with CD437, in regards to SiNur77. The results 
need to be reproduced before drawing any conclusions. 
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Due to lack of time, no proper loading control has been enclosed in this preliminary 
study, instead a copy the amido-black staining of total protein content on the membrane 
has been enclosed.   
 
4. Discussion 
 
Previous studies have shown that the synthetic retinoid, CD437, has a strong 
antiproliferative effect in many cell lines, an effect contributed to by both growth arrest 
and increased cell death (97). The results from our experiments with CD437 in the two 
melanoma cell lines are in accordance with these findings. In both cell lines, treatment 
with CD437 resulted in a marked reduction of cells relative to the control. The 
antiproliferative effect was first studied visually by the use of microscope. The findings 
were further confirmed by counting cells using trypan blue and the MTS assays. Both the 
MTS and the cell count showed the same tendency, with a growth inhibition relative to 
the control of respectively 77% and 92% in FEMX1, and 54% and 84% in WM239, after 
72hrs treatment with 1μM CD437. The results from the MTS assay showed less growth 
inhibition than the cell count. A study comparing different methods for assaying 
proliferation suggests that MTT and MTS-based assays underestimates the 
antiproliferative effects, suggesting the importance of careful evaluation whilst using the 
method (104). Either way, all three proliferation assays performed showed a profound 
antiproliferative effect of CD437. 
The growth inhibitory effect was demonstrated to be both duration and concentration 
dependent. Similar findings have been made in other studies 
(70;74;86;89;92;97;100;105;106). The effect was more pronounced in FEMX1 than in 
WM239 cells. FEMX1 proliferates approximately 50% faster than WM239, as seen in the 
control cells, and it may be speculated that CD437 is more effective in rapidly 
proliferating cells.  
It has previously been shown that the antiproliferative effect of CD437 is, at least 
partially, due to cell cycle arrest (7;10;70;86;89;91;92;106-108). To further assess the 
antiproliferative property of CD437, in FEMX1 and WM239 cells, a cell distribution 
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assay was preformed using flow cytometry. Whereas FEMX1 cells gradually were 
arrested in S-phase, the WM239 cells were halted in G1 upon CD437 treatment. In 
agreement with this, cell-dependent cycle arrests, mediated by the retinoid, have been 
suggested in several studies, as described in ‘1.2.11 CD437s effect on the cell cycle’. 
Treatment with lower concentration (0.1μM CD437) yielded little effect, in regards to 
alterations in cell cycle distribution (not shown). Similar results have also been found in 
human gastric cancer cell lines treated with 0.1μM CD437, suggesting a higher dosage is 
needed for an arrest to occur (91).  
It must be stressed that there is a certain improvement potential to the technique used in 
our study, in regards to assessing cell cycle distribution. Due to the antiproliferative 
effects of CD437, a discrepancy in the relative amount of cells in the control and treated 
samples emerged. Prior to the dying procedure it would have been favorable to count the 
cells in order to make suspensions with an approximately equal amount of cells. The 
uneven concentration of cells in the different samples made it difficult to compare the 
relative location of the distribution peaks. In samples with fewer cells, peaks were shifted   
further to the right due to differences in voltage, compared to samples with larger 
quantities of cells (Trond Stokke, personal communication). To surpass this problem, 
approximately equal amounts of control cells and treated cells were mixed, thus making it 
possible to recognize the relative location of the CD437 mediated arrests.  
In addition, the low concentration of cells in the treated samples caused a limited cell 
count, and thus more ragged curves. Never the less, the cell cycle arrests could clearly be 
distinguished. 
 
To further elucidate the mechanisms explaining the observed cell cycle arrest, expression 
of different cyclins was assessed using western blotting. 
Treatment with CD437 for 24 hrs resulted in a decrease in cyclin D1 in FEMX1, a 
finding suggesting G1-arrest or delayed progression through the G1-phase. The observed 
increased expression of cyclin E and A following CD437 treatment are somewhat 
surprising as these cyclins are generally associated with the G1/S and S-phase progression 
(54). However, in accordance with our findings, CD437 mediated S-phase arrest in 
hepatoma cells was accompanied by an elevation in cyclin A (100). In addition, a 
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decrease in cyclin D has been found following treatment with CD437 in other cells 
arrested in S-phase (8). As opposed to our findings, CD437 has been shown to either 
increase/decrease the expression of cyclin B/B1 respectively, whilst simultaneously 
halting the cells in S-phase(88;109). Thus, the exact role of cyclins in CD437-mediated 
S-phase arrests has not been determined.  
In contrast to FEMX1 cells, the G1-phase arrest observed in WM239 cells was not 
accompanied by changes in the overall protein levels of cyclins, suggesting cell line 
specific differences. Cell cycle arrests may have other causes than alterations in cyclin, as 
will be further discussed below. 
 
In addition to changes in the expression of cyclins, an increase in the levels of the 
transcription factor E2F-1 has been reported to accompany CD437-mediated S-phase 
arrest (88;92). The tumor suppressor pRb guards the checkpoint between the G1/S phases, 
by suppressing the transcription factor E2F (which comes in several isoforms, including 
E2F-1). E2F-1 is released from pRb in mid- to late G1 phase, and can thus transcribe 
genes that contribute to the entry into S phase. Once the cells have entered S-phase, the 
cyclin A/CDK2 complex will bind to E2F-1, by so hindering its DNA binding function. 
A deregulation in the binding between cyclin A/CDK1 and E2F-1 may cause an S-phase 
arrest (110). Treatment with CD437 has previously been shown to increase the E2F-1 
stability, thus causing an up-regulation in its overall protein expression, and a subsequent 
S-phase arrest (88). In accordance this, treatment with CD437 caused an increase in the 
expression of E2F-1 in FEMX1 cells.    
It is well documented that an increased expression of CKIs may cause the cell cycle to 
halt. The expressions of p27 and p21 were thus evaluated following treatment with 
CD437. In both FEMX1 and WM239 cells, a marked elevation of p21 was detected, 
whereas p27 remained unaltered. The cell cycle regulator p21 can bind to CDK 2/4/6, and 
by so inhibit their action, causing the cell cycle to halt. An increase in p21 protein 
expression has previously been associated with both S-phase- and G1 arrests, mediated 
by CD437 (8;70;91;92;100;108;109). 
p53 is another important regulator of the cell cycle, and has been shown to activate 
transcription of p21 (60). An elevation in p53 levels can be seen in response to  DNA 
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damage, and has been found to arrest cells (111;112). Following treatment with CD437, a 
clear increase in the expression of p53 was detected in both FEMX1 and WM239, 
providing a possible explanation to the elevated levels of p21. In agreement with this, p53 
has previously been suggested to cause cell cycle arrest in cells treated with CD437 (70). 
On the other hand, it should be noted that induction of p21 may also occur in a p53-
independent manner, thus suggesting that other regulatory proteins may be involved 
(113). In accordance with this, elevation of p21 following treatment with CD437 has 
been reported to be independent of p53 in human lung cancer cell lines (114).  
 
The relative reduction of cells following the exposure to CD437 can thus be, at least 
partially, explained by cell cycle arrest. However, studies have previously suggested that 
treatment with CD437 can trigger apoptosis in a variety of cancer cell lines (1;5-9;66-
70;73-77;84;86;87;89;91;92;100;106;108;109;115-119). In order to elucidate whether the 
antiproliferative effect of CD437 could also involve increased cell death; a cell count 
using trypan blue was performed. Treatment with 1μM CD437 for 72 hrs resulted in 
respectively 45% and 37% dead cells in FEMX1 and WM239.  
Trypan blue dyes cells with defective cell membranes, yet the method is also used to 
evaluate apoptotic cells, which per definition have intact membranes. Cells undergoing 
apoptosis in vivo will usually be engulfed by circulating phagocytes or neighboring cells, 
due to the exposure of phosphatidyl serine on the cell surface. When apoptotic cells take 
up trypan blue from the medium, it is usually due to cells undergoing a process of 
‘secondary necrosis’, as a response to not being eaten (120). Thus both necrotic and 
apoptotic cells can potentially be dyed with trypan blue, however, the amount of 
apoptotic cells might be underestimated. 
To elucidate whether the dying cells are undergoing apoptosis, measurements of its 
biochemical and morphological features must be employed. The term ‘apoptosis’ 
describes cells with morphologically similar features, however it should be kept in mind 
that different subgroups may display diverse biochemical features (35). At least two 
independent assays should therefore be employed to determine apoptosis, yielding a 
similar result. 
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The effect of CD437 on cell morphology was visually evaluated by the use of a light 
microscope, in collaboration with an experienced pathologist. Cells displaying 
morphological features associated with apoptosis were found in both FEMX1 and 
WM239, such as; rounding-up of the cell, retraction of pseudopodes, reduction in cellular 
volume, plasma membrane blebbing and signs of chromatin condensation. These results 
suggest that CD437 can induce apoptosis in our cell lines.  
 
Oligonucleosomal DNA fragmentation is a morphological characteristic of apoptotic 
cells. It is, however, not an exclusive requirement for apoptosis, cells have been found to 
undergo apoptosis without showing signs of DNA breakage (35).  
Never the less, the DNA fragmentation, as assessed by TUNEL assay, found in WM239 
after 72 hrs exposure to CD437, indicates an on going apoptotic process. Fragmentation 
of DNA following treatment with CD437 has been reported in other cell lines (106;118). 
To our surprise, the TUNEL assay showed no DNA fragmentation in FEMX1. There 
might be several explanations to this. As discussed over, apoptosis might occur without 
DNA fragmentation, although this is more an exception than the rule. Interestingly, a 
previous study using FEMX cells (the progenitor of the FEMX1 cell line) showed no 
increase in FITC intensity after treatment with an immunotoxin. The cells did, however, 
display a range of other apoptotic features (121). Thus, it might be possible for apoptosis 
to occur without DNA fragmentation in this cell line. Another explanation to the missing 
DNA fragmentation could be technical problems, although this seems unlikely. The 
results have been reproduced three times, whilst simultaneously yielding an increase in 
FITC intensity in the treated WM239 cells. The FITC-positive WM239 cells might thus 
work as a positive control for the method.  
Another way of detecting apoptosis in cells is to examine the expression and activity of 
key components involved (35). The caspases are known as the executers of apoptosis. 
These cystein proteases are synthesized as zymogens that upon cleavage can be activated 
(122). The presence of proteolytically active caspases can be used as a marker for 
apoptosis; however, it can not be used as an exclusive means to define it (35). To further 
elucidate whether CD437 could trigger the intrinsic pathway of apoptosis, western blot 
analysis was used to examine a potential cleavage of caspase 9. Activation of caspase 9 
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requires the release of cytochrome c from the mitochondria, and hence MOMP (41). In 
both cell lines, activation of caspase 9 was found after 24 hrs of treatment with 1μM 
CD437. These results suggest that cytochrome c must have been released from the 
mitochondria, which again indicates that CD437 can activate the intrinsic pathway in our 
cell lines.  
A downstream target of caspase 9 is caspase 3, an effector caspase responsible for 
executing many of the apoptotic changes in the cell (41). Following treatment with 
CD437, activation of caspase 3 was found in FEMX1 cells. Surprisingly, WM239 
showed no signs of caspase 3 cleavage. One of the targets of caspase 3 is the DNA repair 
enzyme, PARP. The activation level of PARP depends on the mechanism triggering it. 
Mild cases of DNA damage lead to activation of DNA repair mechanisms, whereas 
severe damages induce over-activation of PARP and thus necrosis. Active apoptotic 
proteases, such as caspase 3 and -7, can on the other hand, deactivate PARP by cleaving 
it, thus inhibiting its DNA-repairing abilities. Cleavage of PARP can hence be used as a 
marker for apoptosis (99;123). A profound cleavage of PARP was seen following 
treatment with CD437 in both cell lines. The PARP cleavage found in WM239 suggests 
that another apoptotic protease, such as caspase 7, must be active in these cells. In 
consistency with these results, previous studies have also reported cleavage of caspases 
and PARP, following treatment with CD437 (70;92).  
 
CD437 has previously been shown to induce apoptosis through activation of caspase 8 
(124). In consistency with these results, activation of caspase 8 was seen following 
treatment with CD437 in both FEMX1 and WM239. Cleavage of caspase 8 is associated 
with activation of death receptors, and thus activation of the extrinsic pathway of 
apoptosis (122). It has previously been found that p53 may trigger the extrinsic pathway 
by stimulating the transcription of Fas and DR5 (death receptors) (125).  Hence, it can be 
speculated whether the observed increase of p53 may sensitize the cell to extracellular 
death signals, leading to the activation of the extrinsic pathway and a subsequent caspase 
8 activation. Studies have on the other hand suggested that caspase 8 activation might be 
induced by ER stress, and not exclusively through the binding of a death ligand (126). 
Either way, the cleaved caspase 8 may now activate caspase 3/7. 
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Activation of caspase 8 may also activate the pro-apoptotic Bcl-2 member, Bid, which 
upon cleavage can trigger the intrinsic pathway of apoptosis (127). Cleavage of Bid 
following treatment with CD437 was not observed in either of our cell lines.  
 
The Bcl-2 family consists of both pro- and anti-apoptotic proteins, a shift in their relative 
balance can lead to the activation of the intrinsic pathway of apoptosis (128). Previous 
studies have shown that CD437 can trigger MOMP and thus the intrinsic pathway 
(73;76). In order to investigate the effect of CD437 on the protein expression of various 
members of the Bcl-2 family, western blot analysis was performed. No marked 
alterations were found in either cell line, in regards to the tested pro- and anti-apoptotic 
Bcl-2 proteins expression. It should be noted that the Bcl-2 family consists of several 
other proteins that have not been examined, such as Bcl-w, Ai, Bcl-B, Bak, Bik, Bmf, 
Hrk, Noxa and Puma. It should be mentioned that several of these factors can be induced 
by p53 (43).    
As mention earlier, none of the tested members of the Bcl-2 family displayed any 
pronounced alterations following the treatment. This might, however, not be the actual 
situation, not all Bcl-2 members have been examined, as well as the apoptotic shift 
leading to the MOMP might have occurred earlier. To present an alternative explanation; 
a study has shown that the orphan nuclear receptor, Nur77, may transform the Bcl-2 in to 
a ‘killer’, thus causing release of cytochrome c (129). An increase of Nur77 was seen in 
both cell lines following treatment with CD437. Yet another possibility; several ER 
membrane proteins have been shown to interact with the anti-apoptotic members of the 
Bcl-2 family, thus reducing their anti-apoptotic activities and causing a subsequent 
release of cytochrome c from the mitochondria (130;131).  
Following these scenarios, the protein-protein interaction would not cause any shift in the 
overall protein expression of the anti-apoptotic Bcl-2 members.  
IAPs are anti-apoptotic proteins which may bind to caspases, thus inhibiting their 
activation. Members of the IAP family, such as survivin, livin and xiap, may be inhibited 
by apoptotic proteins released following MOMP (42). Treatment with CD437 resulted in 
a decrease of survivin in WM239. To our understanding, no such result has previously 
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been reported following treatment with CD437. However, the finding is in consistency 
with the on-going apoptosis in the WM239 cells. 
Whilst central in the regulation of the cell cycle, the tumor suppressor protein p53 also 
plays an important role in triggering apoptosis (132). As previously discussed, both our 
cell lines displayed a marked increase of p53 following exposure to CD437. The 
expression of p53 is under normal conditions kept low. The protein may, however, be 
activated in response to several stressful situations, leading to its stabilization and 
accumulation in the cell (132). p53 mainly mediate apoptosis through the intrinsic 
pathway. It works both as a transcription factor for the pro-apoptotic genes, as well as by 
hindering the transcription of anti-apoptotic proteins, such as Bcl-2 and IAPs (44). 
Additionally, p53 alone, has been shown to directly target the mitochondria causing a 
MOMP (43). The increase of p53 found in our cells in response to treatment with CD437, 
might thus be a possible explanation to the MOMP and subsequent activation of caspase 
9. Previous studies have reported that the involvement of p53 in CD437 mediated 
apoptosis is cell line specific (68;70;86). 
 
Transcription factors are proteins that may bind to specific sequences of DNA and 
thereby control the transcription of certain genes. Depending on the target genes, 
transcription factors may have an influence on apoptosis (133). A previous study on 
melanoma cells suggests that CD437 may induce apoptosis and growth inhibition through 
the activation and up-regulation of the transcription factor complex AP-1 (7). Members 
of the ATF, c-jun and c-fos protein families are involved in formation of the dimeric AP-
1 complex, giving rise to more than 20 different complexes. The composition of proteins 
both associated with- and directly involved in the AP-1 complex determines its effect, 
such as proliferation, apoptosis or terminal differentiation (134). In order to evaluate the 
effect of CD437 in regards to AP-1 activation, protein expression of p-c-jun (one of the 
three members of the c-jun family) was examined in FEMX1 and WM239 cells. An 
increase of p-c-jun was found in both cell lines after treatment with the retinoid. Since the 
transcriptional activity of c-jun is regulated by phosphorylation (135), the increase of p-c-
jun thus suggests that CD437 may up-regulate its activity in our cell lines. Up-regulation 
of c-jun has been suggested to induce apoptosis in many cell lines (136). On the opposing 
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side, the transcriptional activity of AP-1 usually leads to increased proliferation. Thus the 
antiproliferative effect of many retinoids is thought to be mediated through their anti-AP-
1 activity, which is thought to involve RARs (102). Exactly how activation of AP-1 
complexes mediated by CD437, affects FEMX1 and WM239 remain uncertain, even if 
the retinoids overall effect is anti-proliferative.  
 
The orphan receptor Nur77 has been reported to have a central role in CD437 mediated 
apoptosis (43;45;82;87;137-139). The apoptotic effect of Nur77 is determined by its 
subcellular localization. In addition, its ability to induce death is dependent on both the 
cell type and death stimuli (43). Nur77 may bind to DNA as a monomer, homodimer or 
heterodimer, thus increasing the transcription of genes, which are usually associated with 
survival (43;140). However, studies have shown that Nur77 can, upon the 
heterodimerization with RXR, translocate to the cytoplasma where it interacts with the 
mitochondria (141). Translocated Nur77 can  bind to Bcl-2, causing a conformational 
change which turns Bcl-2 into a pro-apoptotic molecule, thus triggering the release of 
cytochrome c (142). As previously discussed, an increase of Nur77 was observed 
following treatment with CD437 in FEMX and WM239. 
In order to explore the effect of Nur77 following treatment with CD437, its protein 
expression was shut down by the use of siRNA transfection. The lack of Nur77 did not 
affect the expression of p21 following treatment with CD437, which indicates that Nur77 
is not responsible for the induction of p21. Interestingly, the transfected siNur77 
prevented up-regulation of p53 following CD437 treatment in FEMX1. This result is 
preliminary; however it suggests that Nur77 may have an influence on the expression of 
p53. E2F-1 may provide a link between Nur77 and p53; Nur77 has been shown to induce 
the expression of E2F-1 (143), whereas E2F-1 indirectly affects p53 by up-regulating 
proteins involved in stabilizing and activating p53 (144). To further explore this 
possibility, the expression of E2F-1 was determined in the treated siNur77 sample, 
yielding a week decrease in E2F-1 in FEMX1 cells. These results may suggest a possible 
connection.  
The treated siNur77 cells showed a simultaneous decrease of p53, whilst p21 remains 
unaltered, suggesting that induction of p21 is p53-independent. It should be stressed that 
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the results need to be reproduced. They have however been enclosed, as the findings may 
provide new insight in the role of Nur77 in the anti-tumor effects of CD437.   
Several signaling pathways have been shown to play a role in mediating the effects of 
CD437 (10;71;88;89;91;145). Based on these previous findings, five different signaling 
pathways associated with CD437-induced apoptosis were examined. An activation in the 
p38/MAPK signaling pathway was found after 3, 8, 24 hrs treatment in both FEMX1 and 
WM239. In addition, an increase of pAKT was found after 1, 3, 8 and 24 hrs.  
Up-regulation of the p38/MAPK signaling pathway has previously been seen in other cell 
lines following treatment with CD437 (67;84;87). The activation of p38/MAPK has, 
moreover, been suggested to be necessary for Nur77 relocation to the mitochondria and 
subsequent apoptosis, following treatment with CD437 (67;87). In contrast, another study 
showed that activation of p38/MAPK did not to play a direct role in apoptosis, but rather 
was a secondary effect (84). How p38/MAPK affects Nur77 can not be determined from 
our study. It would, however, be interesting to inhibit p38/MAPK and elucidate how it 
affects the expression of Nur77. In addition, AP-1 activation may be mediated through 
the MAP kinase pathways, including p38/MAPK (135), thus providing a possible 
explanation to the activation of AP-1 following treatment with CD437. 
The activation of the PI3K signaling pathway in FEMX1 was unexpected. An increased 
activation of this pathway is usually associated with survival, cell growth and 
proliferation (146). In addition, the PI3K pathway has previous been reported to be 
down-regulated by CD437. This  latter study suggests that pAKT may inhibit the nuclear 
export of Nur77, and thus hinder its pro-apoptotic activities (85). An up-regulation of 
pAKT may be a controversial finding in a cell population characterized by 45% dead 
cells. Perhaps not an adequate explanation, however it is possible; FEMX1 may be a 
heterogeneous cell population. The activation of the PI3K pathway can thus be the reason 
for survival in the other half of the population, following treatment with CD437.  
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5. Conclusion 
 
In the present study, the synthetic retionid, CD437, was shown to have an anti-tumor 
effect on the two melanoma cell lines, FEMX1 and WM239. It was demonstrated that 
CD437 had an antiproliferative effect in both cell lines, contributed to by both cell cycle 
arrests and apoptosis.  These findings are, as discussed, in accordance with previous 
publications on the field. Our results contribute to the growing understanding of the 
mechanisms behind CD437s activities, thus making the retinoid more eligible for further 
testing both in vitro and in vivo.   
 
6. Future Perspectives 
 
The master project has been limited by its time-frame of only nine months. Many ideas 
have arisen during the work on the thesis, but have thus not been investigated. Some of 
these thoughts on future perspectives might be interesting to look into, and are listed 
below as bullet-points; 
  
- In order to get a better understanding of the effect of CD437 it would be useful to 
evaluate its effect in more melanoma cell lines, including cells with mutated p53. 
- To our understanding, the effect of CD437 on normal melanocytes has not been 
elucidated. It would thus be interesting to investigate how these cells are affected 
by exposure to CD437. 
- Expression of Nur77 was elevated following treatment with CD437 in FEMX1 
and WM239. Studies have, as previously discussed, suggested translocation of 
Nur77 to both mitochondria and ER. It would thus be interesting to study CD437-
mediated translocation of Nur77 in our cell lines, by the use of for instance 
confocal fluorescence microscopy. Other studies have suggested that both ER 
(75) and the lysosomes (71) may be involved in CD437-mediated apoptosis. It 
might thus be revealing to investigate how CD437 affects these organelles in 
FEMX1 and WM239, by tracking potential changes in CHOP and . 
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- Sun et al has previously had promising results, in vitro, by combining CD437 and 
TRAIL (118). CD437 were shown to up-regulate the expression of death 
receptors (DR4 and DR5), thus sensitizing the cells for treatment with TRAIL, 
resulting in a synergistic effect. It would be interesting to conduct a similar 
experiment on melanoma cells.  
- A microarray analysis of CD437-induced transcripts have already been conducted 
on a set of melanoma cells (8). It would, however, potentially be useful to include 
more melanoma cells to look for a pattern.  
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8. APPENDIX 
 
8.1 Materials 
 
8.1.1 Cell culture 
 
Cell culture 
- RPMI (Roswell Park Memorial Institute) 1640 media 
(LONZA, Verviers, Belgium) 
- L-glutamine  
(LONZA, Verviers, Belgium) 
- Foetal Bovine Serum (BSA)   
(PAA Laboratories, GmbH, Austria) 
- Trypsin/EDTA (Ethylendiaminetetra-acetic acid disodium salt) 
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(LONZA, Verviers, Belgium) 
- DPBS(Dulbecco’s Phosphate Buffered Saline without Ca and Mg) (LONZA, 
Verviers, Belgium) 
- NaCl (9mg/mL) (Fresenius Kabi Norge A/S, Halden, Norway) 
 
 
Treatment 
- CD437 (synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene 
carboxylic acid (CD437) 
 (Sigma-Aldrich, MO, USA) 
- Dimethyl sulfoxide Hybri-max® (DMSO) (Sigma-Aldrich, MO, USA)  
  
 
Harvesting of cells for protein 
- sterile Phosphate buffered saline (PBS) 
 (LONZA, Verviers, Belgium) 
 
- NP-40 Lysis buffer  
o Lysis buffer (1% NP-40, 10% glycerol, 20mM Tris-HCl (pH 7,5), 137mM 
NaCl, 100mM NaF )  
o Aprotenin (0,02 mg/mL) 
o Phosphatase inhibitor cocktail 1 (10μL/mL)  
o Phosphatase inhibitor cocktail 2 (10μL/mL)  
o PhenylMethaneSulfonyl Fluoride (PMSF) (1mM) 
o Leupeptin (0,02 mg/mL)  
o Pepstatin (0,02 mg/mL)  
o Sodium vanadate (1mM) 
Ingredients in the NP-40 lysis buffer are purchased from Sigma-Aldrich. 
 
Harvesting of cells for flow cytometry 
- Sterile Phosphate Buffered Saline (PBS) 
-  (LONZA, Verviers, Belgium) 
- Methanol  (Merck, Damstadt, Germany) 
 
Protein measurement 
- Sterile H2O  (B. Braun Medical AS, Vestskogen, Norway) 
- BioRad Protein Assay (Bradford)  (BioRad, (Life Science), Oslo, Norway) 
 
 
 
 
 
 
 83
8.1.2 Western blot 
 
 
Founding of polyacrylamide gels 
 
Reagent  Producer 12 % gel Stacking gel 
30% 
Acrylamide/BIS 
(29:1) 
BioRad Laboratories 12mL  1,34mL 
1.5M Tris-HCl (pH 
8.8) 
Sigma-Aldrich 7,5mL - 
0.5M Tris-HCl (pH 
6.8) 
Sigma-Aldrich 
 
- 2,5mL 
10% Sodium 
dodecyl sulfate 
(SDS) 
Sigma-Aldrich 0,3mL 0,1mL 
Deionized H2O   10,1mL 6mL 
10% Ammonium 
persulfate (APS)  
BioRad laboratories 150µL 50µL 
Temed BioRad laboratories 10µL 5µL 
Total volume  30mL 10mL 
 
6x loading dye 
- 0.5M Tris-HCl (pH 6.8) (0.35M) 
- SDS (10%)  
- Glycerol (0.6M) 
- Dithiothreitol (DTT) (0.6M)  
- Bromphenol Blue (Sigma-Aldrich, Mo, USA) (0.012%) 
 
Molecular weight marker 
- Full-Range Rainbow Weight Marker ((Amersham), GE healthcare, 
Buckinhamshire, UK) 
 
Western Running Buffer (1x) (1000mL) 
- TrizmaBase (Sigma-Aldrich, MO, USA) (pH 8,3) (3,2g) 
- Glycine (BioRad, (Life Science), Oslo, Norway) (14,4g) 
- SDS (1g) 
- H2O (added to a total volume of 1000mL) 
 
Western Transfer Buffer (1x) (1000mL) 
- TrizmaBase (5,8g) 
- Glycine (BioRad, (Life Science), Oslo, Norway) (2,9g) 
- SDS (0,37g) 
- Methanol (200mL) 
- H2O (added to a total volume of 1000mL) 
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PVDF-Membrane 
- Immobilon-PVDF membrane, with pore size 0.45µm  
 (Millipore, MA, USA). 
 
 
Amido Black (1000mL) 
- 1 g Naphtol-Blue-Black (Sigma-Aldrich, MO, USA)  
- 450ml methanol 
- 100ml Acetic Acid 
- 450ml H2O  
 
Discoloring fluid (1000mL) 
- 900mL methanol 
- 80mL H2O 
- 20mL Acetic Acid 
 
TBST 
- TBS (pH 7.6) (Sigma-Aldrich, MO, USA) (1000mL) 
o NaCl (8g) 
o TrizmaBase (2.42g)  
o H2O 
- Tween®20 Sigma Ultra (Sigma-Aldrich, MO, USA) (0.05-0.25%) 
 
Hybridization 
- Dry non-fat milk (BioRad, (Life Science), Oslo, Norway) 
- BSA (Sigma-Aldrich, MO, USA)  
 
Detection of proteins 
- ECL reagent  
 (Amersham ECL plus western blotting system, GE healthcare bio-Sciences Corp. 
NJ, USA) 
- XOMat UV plus film (Kodak) 
 
Instruments  
- Electrophoresis; Hoefer SE400 Gel Electroforesis Unit (Amersham) 
- Blotting cell; Trans-blot DF (Bio-Rad laboratories) 
- Developer; AGFA Curix 60 (AGFA) 
 
8.1.3 Cell counting by the use of trypan blue dye 
-  Trypan blue (Merck, Stockholm, Sweden) 
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8.1.4 MTS 
- CellTiter 96® AQueous One Solution (Promega, WI, USA) 
 
Plate reader 
- ASYS UVM340 (Fisher Scientific, Oslo, Norway) 
 
8.1.5 Flowcytometry 
- Triton TX100 (Sigma-Aldrich, MO, USA)  
 
- Terminal Transferase recombinant (Roche Diganostics, Mannheim, Germany) 
- Tdt kit including;  
o 5x Reaction buffer (1x) 
o CoCl2 (1,5mM)  
o Tdt (160U)  
o Biotin-16-dUTP (0,5nmol) 
o DTT (0,1mM)  
o Ionized H2O  
  
- 1/50 Streptavidin-FITC solution (volume pr. Sample: 100μL) 
o Streptavidin-FITC (Amersham, GE healthcare, Buckinhamshire, UK) (2 
μL) 
o 3% w/v nonfat dry milk in 0,1% Triton HX100 1xPBS (98μL) 
 
- 1/250 Hoechst solution (volume pr. Sample: 500μL) 
o 0,1 % Triton HX100 1xPBS (498μL) 
o Hoechst 33258 (2μL) (Sigma-Aldrich, MO, USA)  
 
- Instrument: LSR II UV laser 
- PC-based FACS DiVa software. 
 
8.1.6 Transfection 
- Lipofectamine™ RNAiMAX Cat. No. 13778-075 (Deliveredby: Invitrogen, CA, 
USA) 
- Optimem®I  
 (Invitrogen, CA, USA) 
- SiNR4A1, Reference sequence; ‘NM 002135,3’ (Invitrogen Corporations, CA, 
USA). 
- SiCtr (Invitrogen Corporations, CA, USA). 
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8.2 Antibodies used for Western Blots  
 
Primary antibody 
(catalog number) 
Supplier Size 
(kDa) 
Dilution of 
primary 
antibody 
Secondary  
antibody 
Dilution of 
secondary 
antibody 
Akt  
#9272 
 
Cell Signaling 
Technology Inc, MA, 
USA. 
60 1/500 in 1X 
TBS, 0.1% 
Tween-20 
with 5% 
BSA. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA. 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
A-tubulin 
DM1B 
Calbiochem® 
Merck Chemicals Ltd, 
Nottingham,UK. 
55 1/333 in 1X 
TBS, 
0.25% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.25% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Bax 
Ab1 Clone 2D2 
NeoMarkers, Thermo 
Fisher Scientific Inc, CA, 
USA. 
18, 21 1/200 in 1X 
TBS, 
0.25% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.25% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Bcl-2 
M0887, Clone 124 
DakoCytomation, 
Glostrup, Denmark. 
26 1/1000 in 
1X TBS, 
0.25% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.25% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Bcl-xl 
#2762 
Cell Signaling 
Technology Inc, MA, 
USA. 
30 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Bid 
#2002 
Cell Signaling 
Technology Inc, MA, 
USA. 
22, 15 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Bim 
Rbxbim/bod 
AB17003 
 
Millipore Corporate, MA, 
USA. 
23, 26 1/2500 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
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Caspase 3 
AF-605-NA 
R&D Systems Inc, MN, 
USA. 
16, 18, 
20, 32  
1/2000 in 
1X TBS, 
0.05% 
Tween-20 
with 2% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Goat 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.05% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Caspase 8 
#9747 
Cell Signaling 
Technology Inc, MA, 
USA. 
18, 43, 
57 
1/1000 in  
1X TBS, 
0.1% 
Tween-20 
with 5% 
BSA. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Caspase 9 
#9502 
Cell Signaling 
Technology Inc, MA, 
USA. 
47, 37, 
35, 17 
1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Cyclin A 
Sc-751 
Santa Cruz 
Biotechnology Inc, CA, 
USA. 
50, 55 1/1000 in 
1X TBS, 
0.25% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.25% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Cyclin B1 
#4138S 
Cell Signaling 
Technology Inc, MA, 
USA. 
60 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
BSA. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Cyclin D1 
SP4 
NeoMarkers, Thermo 
Fisher Scientific Inc, CA, 
USA. 
36 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
 
Cyclin D3 
#2936 
Cell Signaling 
Technology Inc, MA, 
USA. 
31 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
 
 
 
 
 
 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1 
Tween-20 
with 5% w/v 
nonfat dry 
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E2F-1 
Sc-251 
Santa Cruz 
Biotechnology Inc, CA, 
USA. 
60 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Egr-1 
Sc-189 
Santa Cruz 
Biotechnology Inc, CA, 
USA. 
80 1/1000 in 
1X TBS, 
0.05% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.05% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
ERK2 
Sc-154 
Santa Cruz 
Biotechnology Inc, CA, 
USA. 
42 1/5000 in 
1X TBS, 
0.25% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.25 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
IκBα 
#9242 
Cell Signaling 
Technology Inc, MA, 
USA. 
39 1/1000 in  
1X TBS, 
0.1% 
Tween-20 
with 5% 
BSA. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
IκBα-p 
#9246 
Cell Signaling 
Technology Inc, MA, 
USA. 
40 1/1000 in 
1X TBS, 
0.05% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.05% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Livin 
IMG-347 
BioSite Incorporated, 
CA, USA. 
37, 39 1/333 in 1X 
TBS, 
0.05% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.05% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Mcl-1 
Sc-819 
Santa Cruz 
Biotechnology Inc, CA, 
USA. 
32, 40 1/500 in 1X 
TBS, 
0.05% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
 
 
 
 
 
 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.05% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
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Nur77 (p15) 
#35595 
Cell Signaling 
Technology Inc, MA, 
USA. 
77 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
p21 (DCS60) 
#2946 
Cell Signaling 
Technology Inc, MA, 
USA. 
21 1/3000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
p27/Anti-KIPI 
#610242 
BD Biosciences 
Pharmingen, NJ, USA. 
27 1/1000 in 
1X TBS, 
0.05% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.05% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
 
p38 
pTpY180/182/ 44-
684G 
 
BioSource/Invitrogen 
Corporation, CA, USA. 
38 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 3% 
BSA. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
p53 
Sc-126 
Santa Cruz 
Biotechnology Inc, CA, 
USA. 
53 1/1000 in 
1X TBS, 
0.05% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.05% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
pAKT (Ser437) 
#4058 
Cell Signaling 
Technology Inc, MA, 
USA. 
60 1/500 in 1X 
TBS, 0.1% 
Tween-20 
with 5% 
BSA. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
PARP 
#9532 
Cell Signaling 
Technology Inc, MA, 
USA. 
89, 
116 
1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
BSA. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
 
 
 
 
 
 
 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
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p-c-Jun 
#62615 
Cell Signaling 
Technology Inc, MA, 
USA. 
48 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
BSA. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
pMAPK (Anti-
active® MAPK) 
pTEpY 
#V8031 
Promega Corporation, 
WI, USA. 
42, 44 1/1000 in 
1X TBS, 
0.05% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.05% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
pP38 
(Thr180/Tyr185) 
#4631 
Cell Signaling 
Technology Inc, MA, 
USA. 
 
43 
 
 
 
 
 
1/500 in 1X 
TBS, 0.1% 
Tween-20 
with 5% 
BSA. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
pSAPK/JNK 
#9255 
Cell Signaling 
Technology Inc, MA, 
USA. 
46, 54 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Mouse 
WM401B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
SAPK/JNK 
#9258 
Cell Signaling 
Technology Inc, MA, 
USA. 
49, 54 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
BSA. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Survivin 
AF886 
R&D Systems Inc, MN, 
USA. 
19 1/2000 in 
1X TBS, 
0.05% 
Tween-20 
with 1% 
w/v nonfat 
dry milk. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.05% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
Xiap 
#2045 
Cell Signaling 
Technology Inc, MA, 
USA. 
53 1/1000 in 
1X TBS, 
0.1% 
Tween-20 
with 5% 
BSA. 
HPR- 
conjugated 
Anti-Rabbit 
WM402B 
Promega 
Corporation, 
WI, USA 
1/5000 in 1X 
TBS, 0.1% 
Tween-20 
with 5% w/v 
nonfat dry 
milk. 
 
 
 
